Prediabetes Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Biguanide is the fastest growing sector, North America is the largest market

The Global Prediabetes Market is projected to expand significantly, increasing from USD 351.71 million in 2025 to USD 664.63 million by 2031, demonstrating an impressive compound annual growth rate (CAGR) of 11.19%. This market encompasses various solutions, including diagnostic technologies, pharmaceutical treatments, and digital health tools, all aimed at identifying and managing intermediate hyperglycemia before it advances to type 2 diabetes. Key factors propelling this growth are the rising global rates of obesity and sedentary lifestyles, which highlight the critical need for early preventive healthcare to reduce the long-term financial strain associated with chronic illnesses.

Additionally, the increasing implementation of government-supported screening programs and public health campaigns that advocate for preventive care is significantly boosting the demand for solutions that enable early detection and effective management of prediabetes.Despite this growth, a primary obstacle to market expansion is the low diagnostic rate and insufficient public understanding of prediabetes's seriousness. A substantial number of individuals remain undiagnosed because prediabetes often presents without symptoms, thereby limiting the potential patient base for pharmacological and monitoring products. Data from the International Diabetes Federation in 2024 indicates that approximately 635 million adults globally were living with impaired glucose tolerance, illustrating a considerable disparity between the condition's high prevalence and the relatively small number of individuals who are actively seeking or receiving clinical attention.

Market Drivers

The increasing global incidence of obesity and sedentary lifestyles serves as a key driving force for the Global Prediabetes Market. Since higher body weight negatively affects insulin sensitivity, the growing population with elevated body mass index expands the potential user base for preventive health interventions. This demographic trend is prompting healthcare systems to focus more on weight management to prevent metabolic complications.

The World Obesity Federation's 'World Obesity Atlas 2024' (March 2024) projects that by 2035, the number of adults living with obesity will reach 1.53 billion, a substantial increase that stimulates the creation of lifestyle modification programs and diagnostic tools designed to reverse metabolic risk factors before they worsen.Moreover, the introduction of innovative pharmacological treatments for weight management is transforming the therapeutic landscape.

Newer glucagon-like peptide-1 receptor agonists offer powerful ways to slow down disease progression, with clinical evidence demonstrating their capacity to prevent the transition to type 2 diabetes. For instance, the 'SURMOUNT-1 study results' from Eli Lilly and Company (August 2024) revealed that weekly tirzepatide injections significantly cut the risk of developing type 2 diabetes by 94% in adults with prediabetes and obesity, thus confirming the value of pharmacotherapy in preventive care. Regionally, the market's significant size is apparent; in 2024, about 97.6 million adults in the United States had prediabetes, according to the Centers for Disease Control and Prevention, indicating a large population that could benefit from these treatments.

Market Challenges

A significant impediment to the expansion of the Global Prediabetes Market is the extensive under-diagnosis, largely due to the condition's predominantly asymptomatic nature. Unlike many chronic illnesses that manifest with immediate or severe symptoms, prediabetes typically progresses unnoticed, leaving millions unaware of their health status. This lack of visible symptoms creates a substantial divergence between the high prevalence of prediabetes and the actual demand for clinical interventions. Since individuals do not experience illness, they are less inclined to actively pursue screening or adopt the pharmaceutical and digital health solutions that constitute the market's primary revenue sources.

As a result, the population of patients who are actually seeking treatment is considerably smaller than the total number of affected individuals, which directly constrains the commercial viability of preventive therapies and monitoring technologies.This considerable gap in diagnosis is vividly demonstrated by recent statistics: the Centers for Disease Control and Prevention reported in 2024 that over 80 percent of the nearly 98 million American adults with prediabetes were unaware of their condition. This figure underscores a crucial barrier, as these individuals cannot be enrolled in disease management programs or prescribed preventive treatments without a formal diagnosis. Consequently, manufacturers of diagnostic tests and therapeutic agents encounter a bottleneck where, despite immense theoretical market potential, practical market reach is severely limited because most potential users remain outside the conventional healthcare system.

Market Trends

The Global Prediabetes Market is increasingly leaning towards proactive metabolic management through the incorporation of Continuous Glucose Monitoring (CGM) for individuals without diagnosed diabetes. Manufacturers are introducing over-the-counter biosensors that empower users to observe their glycemic fluctuations and adjust their lifestyle choices without requiring a prescription. This strategy effectively engages the prediabetic population by offering instant feedback on how food and physical activity influence blood sugar levels, thereby circumventing conventional clinical obstacles.

The commercial success of this trend is evident: Fierce Biotech reported in January 2025 (in 'JPM25: Dexcom predicts 2025 growth') that Dexcom's Stelo over-the-counter wearable quickly amassed over 140,000 users and generated $22 million in revenue post-launch, confirming a strong demand for preventive monitoring solutions.Concurrently, the utilization of artificial intelligence (AI) for early risk assessment is addressing the scalability challenges associated with human-focused prevention programs. AI-powered platforms are now capable of analyzing user data to provide tailored coaching, facilitating the cost-effective management of the large, undiagnosed prediabetic demographic. These advanced tools deliver continuous behavioral support with effectiveness comparable to traditional in-person methods. This efficacy was corroborated by Johns Hopkins Medicine in October 2025, where their 'AI-Powered Diabetes Prevention Program Shows Similar Benefits to Those Led by People' report indicated that 31.7% of participants using an AI-driven application achieved official diabetes risk reduction goals, results that mirrored those obtained through human-led interventions.

Key Market Players

• Novo Nordisk A/S
• Valbiotis
• RESVERLOGIX
• Caelus Health
• Scimar
• Boston Pharmaceuticals
• APHAIA PHARMA AG
• AstraZeneca Plc
• Bristol-Myers Squibb Company
• Pfizer Inc

Report Scope

In this report, the Global Prediabetes Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prediabetes Market, by Drug Class:

• Biguanide
• Thiazolidinediones
• Glucagon-like peptide-1 agonists (GLP-1)
• SGLT2 inhibitors
• DPP-4 inhibitors
• Others

Prediabetes Market, by Age Group:

• Children (12-18 years)
• Adults (18-49)
• Elderly (50+)

Prediabetes Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prediabetes Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.